8 results on '"Goerig N"'
Search Results
2. PH-0361: Reactivation of HCMV during RT of the brain results in critical illness and early mortality
- Author
-
Frey, B., Goerig, N., Ina, B., Anna-Jasmina, D., Klaus, K., Klaus, Ü., Manuel, S., Arnd, D., Tobias, E., Ilker, E., Florian, P., Sabine, S., Udo, G., and Rainer, S.F.
- Published
- 2020
- Full Text
- View/download PDF
3. Klinisch relevante CMV-(Re-)Aktivierung während bzw. nach Bestrahlung/Chemotherapie des Gehirns : Korrelation mit neurologischer Verschlechterung und Besserung unter antiviraler Therapie.
- Author
-
Goerig, N., Semrau, S., Frey, B., Korn, K., Fleckenstein, B., Überla, K., Dörfler, A., Putz, F., Gaipl, U., Fietkau, R., Überla, K, Dörfler, A, and Gaipl, U S
- Subjects
BRAIN tumor treatment ,DIAGNOSIS of neurological disorders ,NEUROLOGICAL disorder prevention ,ANTIVIRAL agents ,BRAIN tumors ,CYTOMEGALOVIRUS diseases ,NEUROLOGICAL disorders ,PSYCHOLOGICAL tests ,TREATMENT effectiveness ,DISEASE complications ,VIREMIA ,DIAGNOSIS - Abstract
Copyright of Strahlentherapie und Onkologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
- Full Text
- View/download PDF
4. On PTV definition for glioblastoma based on fiber tracking of diffusion tensor imaging data.
- Author
-
Witulla B, Goerig N, Putz F, Frey B, Engelhorn T, Dörfler A, Uder M, Fietkau R, Bert C, and Laun FB
- Subjects
- Algorithms, Brain Neoplasms pathology, Brain Neoplasms surgery, Follow-Up Studies, Glioblastoma pathology, Glioblastoma surgery, Humans, Magnetic Resonance Imaging, Neoplasm Recurrence, Local prevention & control, Prognosis, Brain Neoplasms diagnostic imaging, Brain Neoplasms radiotherapy, Diffusion Tensor Imaging methods, Glioblastoma diagnostic imaging, Glioblastoma radiotherapy, Radiotherapy Planning, Computer-Assisted methods, Tumor Burden
- Abstract
Radiotherapy (RT) is commonly applied for the treatment of glioblastoma multiforme (GBM). Following the planning target volume (PTV) definition procedure standardized in guidelines, a 20% risk of missing non-local recurrences is present. Purpose of this study was to evaluate whether diffusion tensor imaging (DTI)-based fiber tracking may be beneficial for PTV definition taking into account the prediction of distant recurrences. 56 GBM patients were examined with magnetic resonance imaging (MRI) including DTI performed before RT after resection of the primary tumor. Follow-up MRIs were acquired in three month intervals. For the seven patients with a distant recurrence, fiber tracking was performed with three algorithms and it was evaluated whether connections existed from the primary tumor region to the distant recurrence. It depended strongly on the used tracking algorithm and the used tracking parameters whether a connection was observed. Most of the connections were weak and thus not usable for PTV definition. Only in one of the seven patients with a recurring tumor, a clear connection was present. It seems unlikely that DTI-based fiber tracking can be beneficial for predicting distant recurrences in the planning of PTVs for glioblastoma multiforme., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
5. Idelalisib may have the potential to increase radiotherapy side effects.
- Author
-
Gryc T, Putz F, Goerig N, Ziegler S, Fietkau R, Distel LV, and Schuster B
- Subjects
- Aged, Cells, Cultured, Fibroblasts drug effects, Fibroblasts radiation effects, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell radiotherapy, Lymphocytes drug effects, Lymphocytes radiation effects, Lymphoma, B-Cell drug therapy, Lymphoma, B-Cell radiotherapy, Male, Mucositis pathology, Prognosis, Purines administration & dosage, Quinazolinones administration & dosage, Radiation Tolerance drug effects, Rituximab administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Fibroblasts pathology, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Lymphocytes pathology, Lymphoma, B-Cell pathology, Mucositis etiology, Radiotherapy adverse effects
- Abstract
Introduction: Idelalisib is approved for the treatment of relapsed chronic lymphocytic leukemia together with Rituximab and for monotherapy of follicular B-cell non-Hodgkin's lymphoma and small lymphocytic lymphoma. It is a potent and selective phosphatidylinositol 3-kinase-δ (PI3K-δ) inhibitor. PI3K-δ primarily is expressed in B-cells and prevents effectively proliferation in malignant B-cells., Methods: We provide a detailed report on treatment history and photo documentation of acute adverse effects of radiation therapy with simultaneous Idelalisib medication in one case of B-CLL. Radiosensitivity tests were performed for the index patient under Idelalisib and after the addition of Idelalisib to healthy individuals' blood. Radiosensitivity in human lymphocytes was analyzed with a three color in situ hybridization assay. Primary skin fibroblasts were studied after a treatment with Idelalisib for apoptosis, necrosis and cell cycle using flow cytometry. DNA double-strand break repair was analyzed by γH2AX immunostaining., Results: The index patient presented a strong grade 2 radiodermatitis and grade 3 mucositis after irradiation with 20 Gy and a simultaneous intake of Idelalisib. Irradiations without Idelalisib medication were well tolerated and resulted in not more than grade 1 radiodermatitis. The index patient under Idelalisib had a radiosensitivity of 0.62 B/M which is in the range of clearly radiosensitive patients. A combined treatment of lymphocytes with 2 Gy and 10 nmol/l Idelalisib showed a tendency to an increased radiosensitivity. We found a clear increase of apoptosis as a result of the combined treatment in the Idelalisib dose range of 1 to 100 nmol/l compared to solely irradiated cells or solely Idelalisib treated cells (p = 0.05)., Conclusion: A combined Idelalisib radiotherapy treatment has an increased risk of side effects. However, combined therapy seems to be feasible when patients are monitored closely.
- Published
- 2017
- Full Text
- View/download PDF
6. Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial.
- Author
-
Rühle PF, Goerig N, Wunderlich R, Fietkau R, Gaipl US, Strnad A, and Frey B
- Abstract
Immune responses are important for efficient tumor elimination, also in immune privileged organs such as the brain. Fostering antitumor immunity has therefore become an important challenge in cancer therapy. This cannot only be achieved by immunotherapies as already standard treatments such as radiotherapy and chemotherapy modify the immune system. Consequently, the understanding of how the tumor, the tumor microenvironment, and immune system are modulated by cancer therapy is required for prognosis, prediction, and therapy adaption. The prospective, explorative, and observational IMMO-GLIO-01 trial was initiated to examine the detailed immune status and its modulation of about 50 patients suffering from primary glioblastoma multiforme (GBM) or anaplastic astrocytoma during standard therapy. Prior to the study, a flow cytometry-based assay was established allowing the analysis of 34 immune cell subsets and their activation state. Here, we present the case of the first and longest accompanied patient, a 53-year-old woman suffering from GBM in the front left lobe. In context of tumor progression and therapy, we describe the modulation of the peripheral immune status over 17 months. Distinct immune modulations that were connected to therapy response or tumor progression were identified. Inter alia , a shift of CD4:CD8 ratio was observed that correlated with tumor progression. Twice we observed a unique composition of peripheral immune cells that correlated with tumor progression. Thus, following up these immune modulations in a closely-meshed manner is of high prognostic and predictive relevance for supporting personalized therapy and increasing therapy success. Clinical Trial registration : ClinicalTrials.gov, identifier NCT02022384 (registered retrospectively on 13th of December, 2013).
- Published
- 2017
- Full Text
- View/download PDF
7. Stereotactic radiotherapy of vestibular schwannoma : Hearing preservation, vestibular function, and local control following primary and salvage radiotherapy.
- Author
-
Putz F, Müller J, Wimmer C, Goerig N, Knippen S, Iro H, Grundtner P, Eyüpoglu I, Rössler K, Semrau S, Fietkau R, and Lettmaier S
- Subjects
- Adult, Aged, Aged, 80 and over, Comorbidity, Dizziness diagnosis, Dizziness prevention & control, Female, Germany epidemiology, Hearing Loss diagnosis, Hearing Loss prevention & control, Hearing Tests, Humans, Male, Middle Aged, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local prevention & control, Prevalence, Risk Factors, Treatment Outcome, Vestibular Function Tests statistics & numerical data, Young Adult, Dizziness epidemiology, Hearing Loss epidemiology, Neuroma, Acoustic epidemiology, Neuroma, Acoustic radiotherapy, Radiation Injuries prevention & control, Radiosurgery statistics & numerical data, Salvage Therapy statistics & numerical data
- Abstract
Objective: The aim of this publication is to present long-term data on functional outcomes and tumor control in a cohort of 107 patients treated with stereotactic radiotherapy (RT) for vestibular schwannoma., Patients and Methods: Included were 107 patients with vestibular schwannoma (primary or recurrent following resection) treated with stereotactic RT (either fractioned or single-dose radiosurgery) between October 2002 and December 2013. Local control and functional outcomes were determined. Analysis of hearing preservation was limited to a subgroup of patients with complete audiometric data collected before treatment and during follow-up. Vestibular function test (FVT) results could be analyzed in a subset of patients and were compared to patient-reported dizziness., Results: After a mean follow-up of 46.3 months, actuarial local control for the whole cohort was 100% after 2, 97.6% after 5, and 94.1% after 10 years. In patients with primary RT, serviceable hearing was preserved in 72%. Predictors for preservation of serviceable hearing in multivariate analysis were time of follow-up (odds ratio, OR = 0.93 per month; p = 0.021) and pre-RT tumor size (Koos stage I-IIa vs. IIb-IV; OR = 0.15; p = 0.031). Worsening of FVT results was recorded in 17.6% (N = 3). Profound discrepancy of patient-reported dizziness and FVT results was observed after RT. In patients with primary RT, worsening of facial nerve function occurred in 1.7% (N = 1)., Conclusion: Stereotactic RT of vestibular schwannoma provides good functional outcomes and high control rates. Dependence of hearing preservation on time of follow-up and initial tumor stage has to be considered.
- Published
- 2017
- Full Text
- View/download PDF
8. Improved survival for elderly married glioblastoma patients : Better treatment delivery, less toxicity, and fewer disease complications.
- Author
-
Putz F, Putz T, Goerig N, Knippen S, Gryc T, Eyüpoglu I, Rössler K, Semrau S, Lettmaier S, and Fietkau R
- Subjects
- Adult, Aged, Aged, 80 and over, Brain Injuries psychology, Brain Neoplasms psychology, Causality, Female, Germany epidemiology, Glioblastoma psychology, Hospitalization statistics & numerical data, Humans, Incidence, Male, Marital Status statistics & numerical data, Middle Aged, Radiation Injuries psychology, Retrospective Studies, Risk Factors, Spouses psychology, Survival Rate, Treatment Outcome, Brain Injuries mortality, Brain Neoplasms mortality, Brain Neoplasms radiotherapy, Glioblastoma mortality, Glioblastoma radiotherapy, Radiation Injuries mortality, Spouses statistics & numerical data
- Abstract
Objectives: Marital status is a well-described prognostic factor in patients with gliomas but the observed survival difference is unexplained in the available population-based studies., Methods: A series of 57 elderly glioblastoma patients (≥70 years) were analyzed retrospectively. Patients received radiotherapy or chemoradiation with temozolomide. The prognostic significance of marital status was assessed. Disease complications, toxicity, and treatment delivery were evaluated in detail., Results: Overall survival was significantly higher in married than in unmarried patients (median, 7.9 vs. 4.0 months; p = 0.006). The prognostic significance of marital status was preserved in the multivariate analysis (HR, 0.41; p = 0.011). Married patients could receive significantly higher daily temozolomide doses (mean, 53.7 mg/m² vs. 33.1 mg/m²; p = 0.020), were more likely to receive maintenance temozolomide (45.7 % vs. 11.8 %; p = 0.016), and had to be hospitalized less frequently during radiotherapy (55.0 % vs. 88.2 %; p = 0.016). Of the patients receiving temozolomide, married patients showed significantly lower rates of hematologic and liver toxicity. Most complications were infectious or neurologic in nature. Complications of any grade were more frequent in unmarried patients (58.8 % vs. 30.0 %; p = 0.041) with the incidence of grade 3-5 complications being particularly elevated (47.1 % vs. 15.0 %; p = 0.004)., Conclusion: We found poorer treatment delivery as well as an unexpected severe increase in toxicity and disease complications in elderly unmarried glioblastoma patients. Marital status may be an important predictive factor for clinical decision-making and should be addressed in further studies.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.